PTAB Reverses § 101 Rejection of Receptor-Derived Peptide Claims

The Patent Trial and Appeal Board (PTAB) Reverses 35 U.S.C. § 101 Subject Matter Eligibility Rejection of Receptor-Derived Peptide Claims

People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom. - KFF Health News

People who have taken experimental peptides, such as BPC-157, complain of migraines, eye pain, fatigue, and more. Learning whether these popular but unproven drugs are to blame may become harder if Robert F. Kennedy Jr. fulfills a promise to make them more accessible.

RFK Jr. to Allow Broad Use of Unapproved Peptide Injections

In a unilateral declaration by the health secretary, several injections promoted by online influencers will become widely available. The F.D.A. had advised against the move.

Four Red Flags and One Truth Amid the Peptide Hype - KFF Health News

Experimental peptides are all the rage on longevity and “optimization” podcasts, but a lot of the chatter is misleading.

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

Immune responses to protein and peptide drugs can alter or reduce their efficacy and may be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical measure of protein therapeutic immunogenicity, T cell epitopes in the primary sequences of these drugs are the key drivers or modulators of ADA response, depending on the type of T cell response that is stimulated (e.g. T helper or Regulatory T cells, respectively). In a previous publication on T cell-dependent immunogenicity of biotherapeutics, we addressed mitigation efforts such as identifying and reducing the presence of T cell epitopes or T cell response to protein therapeutics prior to further development of the protein therapeutic for clinical use. Over the past five years, greater insight into the role of regulatory T cell epitopes and the conservation of T cell epitopes with self (beyond germline) has improved the preclinical assessment of immunogenic potential. In addition, impurities contained in therapeutic drug formulations such as host cell proteins have also attracted attention and become the focus of novel risk assessment methods. Target effects have come into focus, given the emergence of protein and peptide drugs that target immune receptors in immuno-oncology applications. Lastly, new modalities are entering the clinic, leading to the need to revise certain aspects of the preclinical immunogenicity assessment pathway. In addition to drugs that have multiple antibody-derived domains or non-antibody scaffolds, therapeutic drugs may now be introduced via viral vectors, cell-based constructs, or nucleic acid based therapeutics that may, in addition to delivering drug, also prime the immune system, driving immune response to the delivery vehicle as well as the encoded therapeutic, adding to the complexity of assessing immunogenicity risk. While it is challenging to keep pace with emerging methods for the preclinical assessment of protein therapeutics and new biologic therapeutic modalities, this collective compendium provides a guide to current best practices and new concepts in the field.

T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020

Immune responses to protein and peptide drugs can alter or reduce their efficacy and may be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical measure of protein therapeutic immunogenicity, T cell epitopes in the primary sequences of these drugs are the key drivers or modulators of ADA response, depending on the type of T cell response that is stimulated (e.g. T helper or Regulatory T cells, respectively). In a previous publication on T cell-dependent immunogenicity of biotherapeutics, we addressed mitigation efforts such as identifying and reducing the presence of T cell epitopes or T cell response to protein therapeutics prior to further development of the protein therapeutic for clinical use. Over the past five years, greater insight into the role of regulatory T cell epitopes and the conservation of T cell epitopes with self (beyond germline) has improved the preclinical assessment of immunogenic potential. In addition, impurities contained in therapeutic drug formulations such as host cell proteins have also attracted attention and become the focus of novel risk assessment methods. Target effects have come into focus, given the emergence of protein and peptide drugs that target immune receptors in immuno-oncology applications. Lastly, new modalities are entering the clinic, leading to the need to revise certain aspects of the preclinical immunogenicity assessment pathway. In addition to drugs that have multiple antibody-derived domains or non-antibody scaffolds, therapeutic drugs may now be introduced via viral vectors, cell-based constructs, or nucleic acid based therapeutics that may, in addition to delivering drug, also prime the immune system, driving immune response to the delivery vehicle as well as the encoded therapeutic, adding to the complexity of assessing immunogenicity risk. While it is challenging to keep pace with emerging methods for the preclinical assessment of protein therapeutics and new biologic therapeutic modalities, this collective compendium provides a guide to current best practices and new concepts in the field.

Opinion | Educate Your Immune System (Published 2016)

Our bodies are confused by this 21st-century world.

F.D.A. Approves New Covid Vaccines, and They Should Be Available Soon

The shots have been approved for people 65 and older, and for younger people with underlying conditions. Others may be able to get them off label.

PTAB Affirms §101 Rejection of Psilocybin Composition, Post-Appeal Prosecution Results in Granted Patent

PTAB Finds that Psilocybin Formulation Is Not a Product of Nature, Further Prosecution Leads to Issued Patent

PTAB Affirms § 101 Rejection of Synthetic Milk Sugar Mixture

The Patent Trial and Appeal Board recently affirmed the 35 U.S.C. § 101 rejection of patent claims for a mixture of three human milk oligosaccharides (HMOs), finding the mixture to be ineligible for patenting

Supplements for MCAS and Histamine Intolerance | The EDS Clinic

Managing Mast Cell Activation Syndrome (MCAS) and histamine intolerance involves a combination of medications, lifestyle changes, and dietary supplements. Supplements, in particular, can play a critical role in helping to reduce symptoms by stabilizing mast cells, reducing inflammation, and improving overall health.

Chris Beiser on Twitter / X

it'd be interesting to quantify the rate at which unaffiliated reddit users have improved on the state of the art for treatment protocols for diseases. my guess is that for 75% of diseases, they're responsible for a greater QoL increase than pharmaceutical companies over 10 years— Chris Beiser (@ctbeiser) June 7, 2021

The Medium is the Message: How Non-Clinical Information Shapes Clinical Decisions in LLMs | Proceedings of the 2025 ACM Conference on Fairness, Accountability, and Transparency

There has been a growing interest in the HCI community to study Health, with particular focus in understanding healthcare practices and designing technologies to support and to enhance these practices. A majority of current health studies in HCI have ...

How To Prompt on Twitter / X

scientist tested a 3.5 billion dollar medical AI against regular chatGPT and it lost on every single one.they just published a paper in nature medicine, and the results are actually mindblowing.they took specialized clinical ai tools and tested them against general-purpose… pic.twitter.com/P7ePLunrDj— How To Prompt (@HowToPrompt__) July 6, 2026